Business Context and Reporting Period
This Form 8-K was filed by Artelo Biosciences, Inc. on March 15, 2022. The report addresses a regulatory communication received from the Nasdaq Stock Market LLC regarding the continued listing status of the Company's common stock (trading symbol: ARTL) and warrants (trading symbol: ARTLW).
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes
The material event reported is the receipt of a notice from Nasdaq granting the Company a second period of 180 calendar days to regain compliance with the minimum bid price requirement.
- Compliance Deadline: September 12, 2022.
- Requirement: The Company must meet the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
- Consequence of Non-Compliance: If the Company fails to regain compliance by the deadline, Nasdaq will provide notice that the common stock will be subject to delisting.
Outlook, Risks, and Management Commentary
Management intends to monitor the closing bid price of its common stock and is considering implementing available options to regain compliance with the minimum bid price requirement. The primary risk identified is the potential delisting of the Company's securities if the $1.00 minimum bid price is not sustained or achieved by the September 12, 2022 deadline. The Company retains the right to appeal a delisting determination to a Nasdaq hearings panel.
Investor Verification Checklist
- Verify the current closing bid price of ARTL common stock relative to the $1.00 threshold.
- Monitor subsequent filings for announcements of capital actions (e.g., reverse stock splits) intended to address the bid price deficiency.
- Confirm the exact date of the compliance deadline (September 12, 2022) and any potential extensions.
- Review the Company's liquidity position in recent 10-Q or 10-K filings to assess its ability to fund operations while addressing listing requirements.